Moody Aldrich Partners LLC Lowers Stock Position in West Pharmaceutical Services Inc. (NYSE:WST)

Moody Aldrich Partners LLC lessened its stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 30.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,244 shares of the medical instruments supplier’s stock after selling 533 shares during the quarter. Moody Aldrich Partners LLC’s holdings in West Pharmaceutical Services were worth $283,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Meeder Asset Management Inc. boosted its stake in West Pharmaceutical Services by 148.6% during the first quarter. Meeder Asset Management Inc. now owns 4,676 shares of the medical instruments supplier’s stock worth $713,000 after buying an additional 2,795 shares during the period. Nuveen Asset Management LLC boosted its stake in West Pharmaceutical Services by 20.8% during the first quarter. Nuveen Asset Management LLC now owns 636,867 shares of the medical instruments supplier’s stock worth $96,963,000 after buying an additional 109,476 shares during the period. Squarepoint Ops LLC boosted its stake in West Pharmaceutical Services by 2.6% during the first quarter. Squarepoint Ops LLC now owns 26,436 shares of the medical instruments supplier’s stock worth $4,025,000 after buying an additional 675 shares during the period. Two Sigma Advisers LP boosted its stake in West Pharmaceutical Services by 58.0% during the first quarter. Two Sigma Advisers LP now owns 10,900 shares of the medical instruments supplier’s stock worth $1,660,000 after buying an additional 4,000 shares during the period. Finally, Mackenzie Financial Corp boosted its stake in West Pharmaceutical Services by 397.9% during the first quarter. Mackenzie Financial Corp now owns 7,000 shares of the medical instruments supplier’s stock worth $1,066,000 after buying an additional 5,594 shares during the period. 90.59% of the stock is owned by institutional investors.

WST has been the topic of several research reports. Bank of America raised shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and set a $280.00 price target on the stock in a research report on Tuesday, July 21st. Zacks Investment Research reissued a “buy” rating and set a $219.00 price target on shares of West Pharmaceutical Services in a research report on Sunday, May 3rd. Finally, BofA Securities raised shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and set a $280.00 price target on the stock in a research report on Tuesday, July 21st.

In related news, SVP David A. Montecalvo sold 14,508 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $264.82, for a total value of $3,842,008.56. Following the sale, the senior vice president now owns 15,732 shares of the company’s stock, valued at $4,166,148.24. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is owned by company insiders.

Shares of WST traded down $0.09 during mid-day trading on Friday, hitting $268.87. 603,081 shares of the company’s stock were exchanged, compared to its average volume of 490,724. The company has a market cap of $19.85 billion, a price-to-earnings ratio of 70.94, a P/E/G ratio of 3.63 and a beta of 1.13. West Pharmaceutical Services Inc. has a fifty-two week low of $124.53 and a fifty-two week high of $273.78. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.11 and a current ratio of 2.96. The stock’s 50-day moving average is $229.94 and its 200-day moving average is $185.69.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $1.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.34. The business had revenue of $527.20 million for the quarter, compared to analysts’ expectations of $496.09 million. West Pharmaceutical Services had a net margin of 14.69% and a return on equity of 19.01%. The business’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 earnings per share. As a group, equities research analysts anticipate that West Pharmaceutical Services Inc. will post 4.27 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Tuesday, July 28th. This represents a $0.64 annualized dividend and a yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 19.75%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: Limitations of the P/E Growth ratio

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.